ALRN Key Statistics, Chart & Performance
The current stock price of ALRN is 2.11 USD. In the past month the price decreased by -1.4%. In the past year, price decreased by -46.38%.
ALRN Latest News, Press Relases and Analysis
ALRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About ALRN
Company Profile
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2017-06-29. The firm is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. The company has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Company Info
AILERON THERAPEUTICS INC
12407 N. Mopac Expy., Suite 250 #390
Austin TEXAS 02472 US
CEO: Manuel C. Alves Aivado
Employees: 15
Phone: 17378021989
AILERON THERAPEUTICS INC / ALRN FAQ
Can you describe the business of AILERON THERAPEUTICS INC?
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2017-06-29. The firm is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. The company has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
What is the current price of ALRN stock?
The current stock price of ALRN is 2.11 USD. The price increased by 9.33% in the last trading session.
Does AILERON THERAPEUTICS INC pay dividends?
ALRN does not pay a dividend.
How is the ChartMill rating for AILERON THERAPEUTICS INC?
ALRN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for AILERON THERAPEUTICS INC?
AILERON THERAPEUTICS INC (ALRN) operates in the Health Care sector and the Biotechnology industry.
ALRN Technical Analysis
ALRN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALRN. The financial health of ALRN is average, but there are quite some concerns on its profitability.
ALRN Financial Highlights
Over the last trailing twelve months ALRN reported a non-GAAP Earnings per Share(EPS) of -3.12. The EPS decreased by -9.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.06% | ||
| ROE | -30.71% | ||
| Debt/Equity | 0 |
ALRN Forecast & Estimates
8 analysts have analysed ALRN and the average price target is 13.26 USD. This implies a price increase of 528.44% is expected in the next year compared to the current price of 2.11.